Patents by Inventor Ross E. Longley
Ross E. Longley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7626043Abstract: The subject invention provides novel biologically active compounds that have utility for use in inhibiting cellular proliferation. Pharmaceutical compositions comprising these compounds are also provided. In a specific embodiment, the compounds and compositions of the subject invention can be used in the treatment of cancer.Type: GrantFiled: August 6, 2007Date of Patent: December 1, 2009Assignee: Florida Atlantic University Board of TrusteesInventors: Amy E. Wright, John K. Reed, Jill Roberts, Ross E. Longley
-
Patent number: 7521474Abstract: The subject invention provides novel compositions of biologically active macrolide compounds which can advantageously be used in blocking cellular proliferation, treatment of cancer, treatment of fungal infections and control of spoilage of food, cosmetic and other consumer items.Type: GrantFiled: July 27, 2006Date of Patent: April 21, 2009Assignee: Florida Atlantic University Board of TrusteesInventors: Amy E. Wright, Shirley A. Pomponi, Peter J. McCarthy, Ying Chen, Ross E. Longley
-
Patent number: 7115756Abstract: The subject invention provides novel compositions of biologically active macrolide compounds which can advantageously be used in blocking cellular proliferation, treatment of cancer, treatment of fungal infections and control of spoilage of food, cosmetic and other consumer items.Type: GrantFiled: June 23, 2004Date of Patent: October 3, 2006Assignee: Harbor Branch Oceanographic Institution, Inc.Inventors: Amy E. Wright, Shirley A. Pomponi, Peter J. McCarthy, Ying Chen, Ross E. Longley
-
Patent number: 7094803Abstract: The subject invention provides novel compositions of biologically active polyketide compounds that can advantageously be used in blocking cellular proliferation and treatment of cancer.Type: GrantFiled: July 12, 2004Date of Patent: August 22, 2006Assignee: Harbor Branch Oceanographic Institution, Inc.Inventors: K. Brian Killday, Amy E. Wright, Shirley A. Pomponi, Ross E. Longley
-
Patent number: 7053118Abstract: The subject invention provides novel compositions of biologically active compounds which can advantageously be used for inhibiting pathological cellular proliferation. The compounds of the subject invention have utility for use in the treatment of cancer, including tumors.Type: GrantFiled: March 6, 2003Date of Patent: May 30, 2006Assignee: Harbor Branch Oceanographic Institution, Inc.Inventors: Sarath P. Gunasekera, Ross E. Longley, Amy E. Wright, John K. Reed
-
Patent number: 6852754Abstract: The subject invention provides novel compositions of biologically active linderazulene terpene compounds which can advantageously be used for treating cancer and stopping cell proliferation.Type: GrantFiled: January 22, 2004Date of Patent: February 8, 2005Assignee: Harbor Branch Oceanographic Institution, Inc.Inventors: Amy E. Wright, Ross E. Longley, Srinivasa Reddy Natala, John K. Reed
-
Patent number: 6835736Abstract: The subject invention provides novel compositions of biologically active discorhabdin compounds which can advantageously be used for inhibiting pathological cellular proliferation. The compounds of the subject invention have utility for use in the treatment of cancer, including tumors.Type: GrantFiled: February 28, 2003Date of Patent: December 28, 2004Assignee: Harbor Branch Oceanographic Institution, Inc.Inventors: Sarath P. Gunasekera, Ross E. Longley, Shirley A. Pomponi, Amy E. Wright
-
Patent number: 6784160Abstract: The subject invention provides novel compositions of biologically active glycosylated pregnene compounds which can advantageously be used for treating cancer and stopping cell proliferation.Type: GrantFiled: April 9, 2003Date of Patent: August 31, 2004Assignee: Harbor Branch Oceanographic Institution, Inc.Inventors: Amy E. Wright, John K. Reed, Ross E. Longley
-
Patent number: 6677370Abstract: Dictyostatin-1 has been found to stabilize microtubules and prohibit their depolymerization to free tubulin. Because of these activities, the dictyostatin compounds can be used in the treatment of a number of diseases in which aberrant cellular proliferation occurs such as drug-sensitive and drug-resistant cancers, autoimmune disorders, and inflammatory diseases.Type: GrantFiled: February 6, 2003Date of Patent: January 13, 2004Assignee: Harbor Branch Oceanographic Institution, Inc.Inventors: Amy E. Wright, Jennifer L. Cummins, Shirley A. Pomponi, Ross E. Longley, Richard A. Isbrucker
-
Publication number: 20030153615Abstract: Dictyostatin-1 has been found to stabilize microtubules and prohibit their depolymerization to free tubulin. Because of these activities, the dictyostatin compounds can be used in the treatment of a number of diseases in which aberrant cellular proliferation occurs such as drug-sensitive and drug-resistant cancers, autoimmune disorders, and inflammatory diseases.Type: ApplicationFiled: February 6, 2003Publication date: August 14, 2003Inventors: Amy E. Wright, Jennifer L. Cummins, Shirley A. Pomponi, Ross E. Longley, Richard A. Isbrucker
-
Patent number: 6576658Abstract: Dictyostatin-1 has been found to stabilize microtubules and prohibit their depolymerization to free tubulin. Because of these activities, the dictyostatin compounds can be used in the treatment of a number of diseases in which aberrant cellular proliferation occurs such as drug-sensitive and drug-resistant cancers, autoimmune disorders, and inflammatory diseases.Type: GrantFiled: February 26, 2001Date of Patent: June 10, 2003Assignee: Harbor Branch Oceanographic Institution, Inc.Inventors: Amy E. Wright, Jennifer L. Cummins, Shirley A. Pomponi, Ross E. Longley, Richard A. Isbrucker
-
Patent number: 6495594Abstract: The subject invention provides novel compositions of biologically active discodermolide compounds which can advantageously be used for immunomodulation and/or treating cancer. The compounds of the subject invention have utility for use in the treatment of cancer, as tubulin polymerizers and as microtubule stabilization agents. The present invention also pertains to the identification of regions of the discodermolide molecule which are responsible for certain aspects of the bioactivity of discodermolide compounds.Type: GrantFiled: February 28, 2001Date of Patent: December 17, 2002Assignee: Harbor Branch Oceanographic Institution, Inc.Inventors: Sarath P. Gunasekera, Ross E. Longley, Richard A. Isbrucker, Gopal K. Paul, Shirley A. Pomponi, Amy E. Wright
-
Patent number: 6476065Abstract: The subject invention provides novel biologically active compounds which are useful for inhibiting cellular proliferation. Because of the biological activity of these compounds, they can be used for immunomodulation and/or treating cancer. In a preferred embodiment, the novel compounds, compositions and methods of use of the subject invention can advantageously be used to inhibit the growth of tumor cells in a mammalian host. More particularly, the subject compounds can be used for inhibiting in a human the growth of tumor cells, including cells of breast, colon, CNS, ovarian, renal, prostate, bone, gastrointestinal, stomach, testicular, or lung tumors, as well as human leukemia or melanoma cells. Specifically exemplified are discalamides A and B.Type: GrantFiled: April 16, 2001Date of Patent: November 5, 2002Assignee: Harbor Branch Oceanographic Institution, Inc.Inventors: Sarath P. Gunasekera, Ross E. Longley, Gopal K. Paul, Richard A. Isbrucker, Shirley A. Pomponi
-
Patent number: 6384187Abstract: The subject invention pertains to a series of cyclic peptides known as the microsclerodermins, which possess unusual amino acids, and which have been observed to inhibit the proliferation of tumor cell lines. The subject invention also pertains to methods useful in inhibiting pathological cellular proliferation in animals, including humans and other mammals. In accordance with the teachings of the subject invention, microsclerodermin compounds can be used to inhibit cellular proliferation including that which is responsible for tumors and other cancers. In a specific embodiment, the novel compositions and methods of use of the subject invention can advantageously be useful in the treatment of a patient hosting cancer cells, for example, inhibiting the growth of tumor cells in a mammalian host.Type: GrantFiled: May 11, 2000Date of Patent: May 7, 2002Assignee: Harbor Branch Oceanographic Institution, Inc.Inventors: Amy E. Wright, Shirley A. Pomponi, Ross E. Longley, Richard A. Isbrucker
-
Publication number: 20020016357Abstract: The subject invention provides novel biologically active compounds which are useful for inhibiting cellular proliferation. Because of the biological activity of these compounds, they can be used for immunomodulation and/or treating cancer. In a preferred embodiment, the novel compounds, compositions and methods of use of the subject invention can advantageously be used to inhibit the growth of tumor cells in a mammalian host. More particularly, the subject compounds can be used for inhibiting in a human the growth of tumor cells, including cells of breast, colon, CNS, ovarian, renal, prostate, bone, gastrointestinal, stomach, testicular, or lung tumors, as well as human leukemia or melanoma cells. Specifically exemplified are discalamides A and B.Type: ApplicationFiled: April 16, 2001Publication date: February 7, 2002Inventors: Sarath P. Gunasekera, Ross E. Longley, Gopal K. Paul, Richard A. Isbrucker, Shirley A. Pomponi
-
Publication number: 20010056118Abstract: Dictyostatin-1 has been found to stabilize microtubules and prohibit their depolymerization to free tubulin. Because of these activities, the dictyostatin compounds can be used in the treatment of a number of diseases in which aberrant cellular proliferation occurs such as drug-sensitive and drug-resistant cancers, autoimmune disorders, and inflammatory diseases.Type: ApplicationFiled: February 26, 2001Publication date: December 27, 2001Inventors: Amy E. Wright, Jennifer L. Cummins, Shirley A. Pomponi, Ross E. Longley, Richard A. Isbrucker
-
Publication number: 20010049387Abstract: The subject invention provides novel compositions of biologically active discodermolide compounds which can advantageously be used for immunomodulation and/or treating cancer. The compounds of the subject invention have utility for use in the treatment of cancer, as tubulin polymerizers and as microtubule stabilization agents. The present invention also pertains to the identification of regions of the discodermolide molecule which are responsible for certain aspects of the bioactivity of discodermolide compounds.Type: ApplicationFiled: February 28, 2001Publication date: December 6, 2001Inventors: Sarath P. Gunasekera, Ross E. Longley, Richard A. Isbrucker, Gopal K. Paul, Shirley A. Pomponi, Amy E. Wright
-
Patent number: 6218419Abstract: The subject application concerns novel compounds with useful biological properties. For example, these compounds can be used as antinflammatory, anti-proliferative, immunomodulatory, and/or neuroprotective agents. Specific examples of the compounds of the subject invention include Secobatzelline A and Secobatzelline B, which can be isolated from marine sponges.Type: GrantFiled: July 8, 1999Date of Patent: April 17, 2001Assignee: Harbor Branch Oceanographic Institution, Inc.Inventors: Sarath P. Gunasekera, Peter J. McCarthy, Ross E. Longley, Shirley A. Pomponi, Amy E. Wright
-
Patent number: 6127406Abstract: Novel analogs of compounds from the marine sponge Discodermia dissoluta have been prepared. These compounds have been shown to have activity against mammalian cancer cells, and can be used in treating human patients which host cancer cells, including leukemia, melanoma, breast, colon, CNS, renal, ovarian, prostate, and lung tumors.Type: GrantFiled: October 5, 1999Date of Patent: October 3, 2000Assignee: Harbor Branch Oceanographic Institution, Inc.Inventors: Sarath P. Gunasekera, Ross E. Longley
-
Patent number: 6087363Abstract: Imidazole and indole compounds were found to inhibit neural nitric oxide synthase (bNOS) activity. Nortopsentin-C inhibited bNOS as well as calcineurin activities suggesting that its actions are directed against calmodulin, a co-factor common to these two enzymes. Two indole compounds, as well as dragmacidin-D, inhibited bNOS, but not calcineurin, activity. Murine macrophage viability and induced NOS (iNOS) activity in cultured cells was also unaffected by these compounds.Type: GrantFiled: July 16, 1999Date of Patent: July 11, 2000Assignee: Harbor Branch Oceanographic Institution, Inc.Inventors: Ross E. Longley, Richard A. Isbrucker, Amy E. Wright